Clinical Trial Update: Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 results for sipuleucel-T (APC8015/Provenge) in asymptomatic, metastatic hormone-refractory prostate cancer were completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Sipuleucel-T (Provenge) (sipuleucel-t)

Snippet

Sponsor: Dendreon | Conditions: Hormone-Refractory Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2010-09-02